Zogenix Secures $50,000,000 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    12671 High Bluff Drive San Diego, CA 92130
  • Company Description
    Zogenix is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders. Founded in 2006, the company currently has two proprietary product candidates in late-stage development. Our lead product candidate, SUMAVEL™ DOSEPRO™ (sumatriptan injection) needle-free delivery system, is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan – the fastest acting migraine medicine – for the treatment of migraine and cluster headache. Our second product candidate, ZX002, is a novel, oral controlled-release formulation of hydrocodone for the treatment of chronic pain.
  • Website
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The financing will be used to satisfy working capital needs in the commercial launch of SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system, the company’s first FDA-approved product, and the ongoing Phase 3 clinical development program of ZX002, a novel oral controlled-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain. Proceeds will also be used to fully repay the outstanding balance of an existing term loan.
  • M&A Terms
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    Scale Venture Partners
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    Chicago Growth Partners

Trending on Xconomy